Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    2002-03
Previous Study | Return to List | Next Study

Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00129376
Recruitment Status : Completed
First Posted : August 11, 2005
Results First Posted : July 5, 2019
Last Update Posted : July 5, 2019
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
Spanish Breast Cancer Research Group

Brief Summary:

Treatment consists of 4 AC cycles followed by 2 weekly docetaxel cycles (12 infusions).

The pathological complete response rate obtained in previous studies is around 12%. The expected pathological complete response rate in this study is 25%. With an alpha error of 0.05 and a beta error of 0.2, and following Simon´s 2 phase test, 19 patients are needed initially. With 2 pathological complete responses, patient recruitment will continue until approximately 61 patients are recruited. Twelve pathological complete responses are needed to confirm the study hypothesis.


Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Doxorubicin Drug: Cyclophosphamide Drug: Docetaxel Phase 2

Detailed Description:

Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks later, docetaxel (36 mg/m2) was administered as a 30-min intravenous infusion, weekly for six weeks (days 85, 92, 99, 106, 113 and 120) followed by a 2-week resting period (8-week cycle). After that, patients received a second docetaxel cycle (infusions on days 141, 148, 155, 162, 169 and 176). Adjuvant chemotherapy and radiotherapy were delivered according to the protocol of each participating center. Hormonal treatment was started after the last chemotherapy infusion in all patients with positive estrogen and/or progesterone receptor tumors and was continued for five years.

Semiquantitative determination of three molecular markers was carried out by immunocytochemical methods. Tissue samples were taken prior to initiation of chemotherapy from the core of the primary tumors. Specimens were sent to a central laboratory for analysis of Topo II, survivin and p27.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 63 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Phase II Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel (T) as Neoadjuvant Treatment for Operable Stage II and IIIA Breast Cancer Patients
Actual Study Start Date : February 2003
Actual Primary Completion Date : July 2005
Actual Study Completion Date : February 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Doxorubicin+cyclophosphamide - Docetaxel
Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles. Later, docetaxel (36 mg/m2) was administered an intravenous infusion, weekly for six weeks followed by a 2-week resting period (8-week cycle).
Drug: Doxorubicin
Other Name: adriamycin

Drug: Cyclophosphamide
Other Name: Cytoxan

Drug: Docetaxel
Other Name: Taxotere




Primary Outcome Measures :
  1. Pathological Complete Response (pCR) Rate [ Time Frame: Up to 29 weeks ]
    Pathological complete response was defined by the Miller & Payne criteria. pCR was defined as no invasive cells identifiable in breast sections at surgery. Response was measured by physical exam and breast imaging before surgery and was evaluated according to the World Health Organization (WHO) criteria. Pathological response after surgery, was based on the proportion of remaining tumor and postchemotherapy changes, evaluating separately the response in the breast and in the axilla lymph nodes.


Secondary Outcome Measures :
  1. Clinical Response Rate (CRR) [ Time Frame: Up to 29 weeks ]

    CRR measured according to the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions, where:

    • Complete Response (CR): disappearance of all target lesions
    • Partial Response (PR): >=30% decrease in the sum of the longest diameter of target lesions
    • Progresive Disease (PD): >=20% increase from smallest sum of longest diameter recorded since treatment started (best response).
    • Stable Disease (SD): Neither PD nor PR

  2. Number of Participants With Over-expression of Topo II (>10% Cells With Nuclear Staining) [ Time Frame: Up to 29 weeks ]
    Paraffin-embedded tumors were processed with standard immunocytochemical techniques. Over-expression of Topo II was defined as >10% cells with nuclear staining.

  3. Number of Participants With Over-expression of Survivin (>1% Cells With Nuclear Staining) [ Time Frame: Up to 29 weeks ]
    Paraffin-embedded tumors were processed with standard immunocytochemical techniques. Tumors with more than 1% of cells with nuclear staining were considered to be over-expressing this protein.

  4. Number of Participants With Over-expression of p27 (>75% Cells With Nuclear Staining) [ Time Frame: Up to 29 weeks ]
    Paraffin-embedded tumors were processed with standard immunocytochemical techniques. Sections were rated according to the percentage of tumor cells nuclei with positive staining (1 = < 25%; 2 = between 25-75% and 3 = > 75%).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent.
  • Patients with breast cancer stages II and IIIA, with histological diagnoses as per true-cut or open biopsy.
  • Negative extension study, including bilateral mammography, thoracic x-ray, computed tomography (CT)-scan or abdominal echography and bone scintigraphy.
  • Analysis of hormone receptor status in primary tumour. It is highly recommended to obtain a tumour tissue sample before start of treatment, and after definitive surgery. These samples will be analysed centrally by Spanish Breast Cancer Research Group (GEICAM).
  • Age >= 18 and <= 70 years old.
  • Performance status as per Karnofsky index >= 80.
  • Minimum life expectancy of 6 months.
  • Electrocardiogram (EKG) 12 weeks before registration to the study. If abnormalities are suspected, cardiac function must be assessed by left ventricular ejection fraction (LVEF).
  • Haematology: neutrophils >= 2.0 x10^9/l; platelets >= 100 x10^9/l; hemoglobin >=10 g/dl.
  • Hepatic function: total bilirubin <= 1 x upper normal limit (UNL); Aspartate aminotransferase (AST) (SGOT) and and Alanine aminotransferase (ALT) (SGPT) <= 2.5 x UNL; alkaline phosphatase <= 5 x UNL.
  • Renal function: creatinine <= 1.5 x UNL; creatinine clearance >= 60 ml/min.
  • Patients able to comply with study requirements.
  • Negative pregnancy test.
  • Adequate contraceptive method during the study and up to 3 months after definitive surgery.

Exclusion Criteria:

  • Previous systemic therapy for breast cancer treatment.
  • Previous treatments with anthracyclines or taxanes for any malignancy.
  • Previous radiotherapy for breast cancer.
  • Bilateral invasive breast cancer.
  • Pregnant or lactating women.
  • Previous motor or sensorial neurotoxicity grade >=2.
  • Other serious pathologies: congestive heart failure or angina pectoris; history of myocardial infarction in the previous year; uncontrolled hypertension (HT) or high risk arrhythmias.
  • History of neurological or psychiatric impairment, precluding patients from providing free informed consent.
  • Active infection.
  • Active peptic ulcer; unstable diabetes mellitus.
  • History of previous or current malignancies other than breast cancer, except for basal skin carcinoma, cervical in situ carcinoma, other tumour diagnosed and treated more than 10 years before, ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS).
  • Chronic treatment with corticoids unless the treatment started > 6 months before registration to the study, and low doses are administered.
  • Substitutive hormonal therapy. This treatment must be interrupted before inclusion in the study.
  • Concomitant treatment with other investigational products or administration in the 30 previous days.
  • Males.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00129376


Locations
Layout table for location information
Spain
Hospital Universitario Germans Trias i Pujol
Badalona, Barcelona, Spain, 08916
Corporació Sanitaria Parc Taulí
Sabadell, Barcelona, Spain, 08208
Hospital de la Ribera
Alcira, Valencia, Spain, 46600
Complejo Hospitalario Universitario A Coruña
A Coruña, Spain, 15006
Hospital General Universitario de Alicante
Alicante, Spain, 03010
Fundación Jiménez Díaz
Madrid, Spain, 28040
Sponsors and Collaborators
Spanish Breast Cancer Research Group
Sanofi
Investigators
Layout table for investigator information
Study Director: Study Director Fundación Jiménez Díaz
Study Director: Study Director Hospital Universitario Marqués de Valdecilla
Additional Information:
Layout table for additonal information
Responsible Party: Spanish Breast Cancer Research Group
ClinicalTrials.gov Identifier: NCT00129376    
Other Study ID Numbers: GEICAM 2002-03
First Posted: August 11, 2005    Key Record Dates
Results First Posted: July 5, 2019
Last Update Posted: July 5, 2019
Last Verified: April 2019
Keywords provided by Spanish Breast Cancer Research Group:
Stage II and IIIA breast Cancer.
Neoadjuvant chemotherapy.
Weekly docetaxel.
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Cyclophosphamide
Docetaxel
Doxorubicin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors